Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

HUTCHMED (China) Limited Sponsored ADR (HCM) vs Prestige Consumer Healthcare Inc. (PBH)

HUTCHMED (China) Limited Sponsored ADR and Prestige Consumer Healthcare Inc. are both Drug Manufacturers Specialty & Generic companies. HUTCHMED (China) Limited Sponsored ADR is the larger, with a market value of $2.4B against $2.2B — 1.1× the size. HUTCHMED (China) Limited Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; Prestige Consumer Healthcare Inc. trades at 13.0×. HUTCHMED (China) Limited Sponsored ADR grew revenue faster over the last twelve months: 245.2% against −1.36%. Prestige Consumer Healthcare Inc. has the higher net margin (15.6% vs −23.6%) and the higher return on invested capital (4.70% vs 0.00%). Across the 18 metrics below, Prestige Consumer Healthcare Inc. leads on 11 and HUTCHMED (China) Limited Sponsored ADR on 7.

Valuation

Metric HCM PBH Drug Manufacturers Specialty & Generic median
P/E n/m 12.98 20.14
P/S n/m 2.00 2.25
P/B n/m 1.15 1.90
Price to free cash flow n/m 9.40 16.54
EV/EBITDA 0.38 12.82 12.29
EV/Sales (0.13) 3.76 2.56
Earnings yield (21.11%) 7.70% (2.99%)
Free cash flow yield 0.00% 10.64% 0.00%

Profitability

Metric HCM PBH Drug Manufacturers Specialty & Generic median
Gross margin 44.40% 53.53% 53.94%
Operating margin 0.00% 26.26% 0.00%
Net margin (23.63%) 15.57% 0.00%
Free cash flow margin 0.00% 21.30% 0.00%
Return on equity 0.00% 9.12% (0.40%)
Return on assets 0.00% 4.30% (3.32%)
Return on invested capital 0.00% 4.70% 0.00%

Growth

Metric HCM PBH Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 245.17% (1.36%) 10.01%
EPS growth (last fiscal year) 1,090.91% (8.86%) —
Revenue growth, 5-year CAGR 19.20% 2.91% 6.74%
Net income growth, 5-year CAGR 0.00% 2.93% 0.00%

Health

Metric HCM PBH Drug Manufacturers Specialty & Generic median
Debt to equity 0.07 1.06 0.05
Current ratio 5.64 3.23 2.31
Net debt to EBITDA 49.29 2.77 0.85

Dividend

Metric HCM PBH Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric HCM PBH Drug Manufacturers Specialty & Generic median
Market cap 2.43b 2.16b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack